With nearly two decades of experience in molecular diagnostics, biotechnology, and life sciences, Andy Moye is a leader in the fields of pathology, oncology, genomics, and precision medicine.

As CEO of Paige, Andy is driving the company’s mission to advance cancer detection, patient care, and treatment through cutting-edge AI technology. Paige aims to transform cancer diagnostics by harnessing the power of tissue-based AI, not only through industry-leading AI products but also by collaborating with labs worldwide to improve patient care.

Under Andy’s leadership, Paige successfully launched Paige Prostate Detect, the first AI-based pathology product authorized by the FDA for cancer detection in prostate biopsies. Andy’s focus extends to the development of disruptive biomarker AI algorithms, empowering pathologists to access previously inaccessible information.

Through this interview, we explore Andy Moye’s insights and experiences, as well as the future of Paige and the impact of AI on cancer diagnostics.

Kindly brief us about yourself and your role as the CEO at Paige.

I have been at the forefront of the molecular diagnostics, biotechnology, and life sciences industries for nearly two decades, focusing on pathology, oncology, genomics, and precision medicine. At Paige, I help drive the company’s mission to advance cancer detection, patient care, and treatment through the development of cutting-edge artificial intelligence technology. We believe using the power of tissue-based AI will transform cancer diagnostics, and our goal is not only to create industry-leading AI products but to work with labs around the world to tap into that power and directly improve patient care.

I am fortunate to have had the opportunity to steer the U.S. launch of Paige Prostate Detect, the first and only AI-based pathology product to receive FDA marketing authorization for in vitro diagnostic (IVD) use in detecting cancer in prostate biopsies. Since then, I’ve focused on leading the company in the development of additional transformative and disruptive algorithms including our biomarker AI algorithms, designed to help pathologists obtain information that they otherwise wouldn’t be able to access. I am excited to see how our continued work in diagnostic and biomarker AI will make an impact.

How has AI impacted cancer research and treatment so far, and what developments are you most excited about?

AI and machine learning is creating a whole new world for cancer treatment and diagnosis.  One of the biggest ways AI can offer value to pathologists is by supporting efficient and confident diagnoses, and many independent studies have shown that Paige AI can deliver this for pathologists around the globe.  But ultimately, we measure success by how many patients’ lives we positively impact – so far, our AI has been used on over 4,000 cases. We expect that number to grow to the tens of thousands over the course of the next year or so, and developments that will help make that happen are the ones that I am most excited about.

Read the Full Interview @ https://ai-techpark.com/aitech-interview-with-andy-moye/